ERITREA INACTIVATED POLIO VACCINE (IPV) SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

<table>
<thead>
<tr>
<th>1. Country</th>
<th>Eritrea</th>
</tr>
</thead>
</table>

2. **Grant Number**: 1518-ERI-25b-X / 15-ERI-08h-Y

3. **Date of Decision Letter**: 31 March 2015

4. **Date of the Partnership Framework Agreement**: 16 April 2013

5. **Programme Title**: NVS, IPV Routine

6. **Vaccine type**: Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine**: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme Duration**: 2015 - 2018

9. **Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement)**:

   Please note that endorsed or approved amount for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>US$157,500</td>
<td>US$302,500</td>
<td>US$238,000</td>
<td>US$698,000</td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant**: US$ 100,000

11. **Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement)**:

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>76,600</td>
<td>147,200</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>74,000</td>
<td>140,100</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>825</td>
<td>1,550</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$157,500</td>
<td>US$302,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency**: UNICEF

13. **Self-procurement**: Not applicable

---

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the programme.
3 This is the total amount endorsed by Gavi for 2015 to 2017.
4 This is the amount that Gavi has approved.
14. **Co-financing obligations:** Not applicable

Gavi’s usual co-financing requirements do not apply to IPV. However, Eritrea is encouraged to contribute to vaccine and/or supply costs for IPV.

15. **Operational support for campaigns:** Not applicable

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with Gavi Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial Clarifications:** Not applicable.

*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. **Other conditions:**

If Eritrea envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Eritrea.

REMINDER: As a Partnership Framework Agreement requirement: "...the government shall maintain, where available at a reasonable cost, all risk property insurance on the Programme assets (including vaccines and vaccine related supplies) and comprehensive general liability insurance with financially sound and reputable insurance companies". In this context, kindly provide Gavi with a copy of such insurance policy to ensure compliance with this requirement.

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes

31 March 2015